Infectious Diseases | Home

Malaysia
Search
Sign In

Infectious Diseases Search

Infectious Diseases

Infectious Diseases

Home News Diseases Conferences Special Reports Multimedia

Original New Drug Application Approvals by US FDA (01 - 15 November 2019)

5 days ago

New drug applications approved by US FDA as of 01 - 15 November 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Anaerobes, S. anginosus among most common bacteria in children with complicated appendicitis

6 days ago

Streptococcus anginosus, aminoglycoside-susceptible Gram-negative bacilli and anaerobes remain the most common bacteria in previously healthy children presenting with complicated appendicitis requiring surgical drainage, reports a study.

Post-surgery infection tied to long-term infection risk

Roshini Claire Anthony, 6 days ago

Individuals who develop an infection within a month of undergoing major surgery may have an elevated risk of developing a subsequent infection within a year as well as an elevated risk of mortality, according to a recent retrospective study.

Comorbidity, secondary infections predict IMV need, death in children with influenza-related LRTI

6 days ago

Neutrophilia, lymphopaenia, secondary bacterial infections (SBIs) and presence of comorbidity are associated with severe clinical course, as well as death, in children with influenza-related lower respiratory tract infection (LRTI), a recent study has found.

Oral antibiotics noninferior to IV antibiotics for K. pneumoniae liver abscess

Roshini Claire Anthony, 08 Nov 2019

Adults hospitalized for liver abscess due to Klebsiella pneumoniae (K. pneumoniae) could be treated with oral rather than intravenous (IV) antibiotics, according to a trial from Singapore.

Dolutegravir: Towards an Optimized Treatment in the Management of HIV

19 Jun 2019

Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.

The Evolving Role of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in Women’s Urogenital Health

12 Jun 2019

Urogenital infections remain a major reason for women to visit their family physician and their subsequent referral to obstetrics and gynaecology or urology specialists. The association between abnormal vaginal microbiota and an increased risk of contracting sexually transmitted diseases (STDs), as well as an increased rate of preterm labour, indicates the need to better understand and manage urogenital health in women. Probiotics are “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”. As such, there is a sound rationale for using probiotics to maintain female vaginal and bladder health.

Paediatric vaccination improves patient adherence, reduces paediatric mortality

17 Dec 2018

At the 40th Malaysian Paediatric Association Annual Congress held on 6 September 2018 at the Ipoh Convention Centre, Dr Yong Junina Fadzil discussed the applications of a hexavalent vaccine in optimizing paediatric vaccination schedules. Meanwhile, Dato’ Dr Musa Mohd Nordin shared his insights into the paediatric influenza ‘landscape’ in the region and highlighted the importance of regularly vaccinating paediatric patients.

Influenza prophylaxis to reduce complications in high-risk populations

01 Jul 2018

Influenza is a highly contagious viral disease, which is primarily spread through water droplets containing strains of the virus. Dr Leong Chee Loon shares his insights into the management of influenza in Malaysia, highlighting the importance of improving vaccination coverage in populations at high-risk of influenza-related complications, such as elderly patients and healthcare practitioners.

Dolutegravir noninferior to low-dose efavirenz in HIV-1 suppression

Roshini Claire Anthony, 29 Aug 2019

Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.

Tsepamo: Potential uptick of neural-tube defects with dolutegravir-based ART

Pearl Toh, 22 Aug 2019

Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.

Dolutegravir-emtricitabine + TAF/TDF combo ADVANCEs as potential HIV-1 treatment

Roshini Claire Anthony, 20 Aug 2019

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Fostemsavir shows sustained virologic suppression in resistant HIV

Pearl Toh, 19 Aug 2019

The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.

Two to TANGO: Dolutegravir-lamivudine combo safe, effective substitute for TAF regimen

Roshini Claire Anthony, 15 Aug 2019

Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).

Single-tablet combo regimen fares well in HIV treatment

Audrey Abella, 06 Aug 2019

The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.

Monthly cabotegravir-rilpivirine favoured by PLHIV

Audrey Abella, 05 Aug 2019

Persons living with HIV (PLHIV) who received monthly long-acting (LA) intramuscular formulations of the INSTI* cabotegravir and the NNRTI** rilpivirine reported higher levels of treatment satisfaction and treatment acceptance, and greater willingness to continue therapy as opposed to a daily oral antiretroviral therapy (ART) regimen, according to patient-reported outcomes of the ATLAS*** and FLAIR# trials presented at IAS 2019.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!